Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer

• Status: Recruiting
• Trial end date: 2026-12-01

Summary

Some patients with limited disease small-cell lung cancer (LD SCLC) are cured after chemo-radiotherapy, but the majority relapse and die from their cancer. Better therapy is needed. Immunotherapy represents the largest advance in cancer therapy in recent years and has demonstrated promising activity in SCLC. In this study we will investigate whether atezolizumab prolongs survival in LD SCLC patients who have undergone chemo-radiotherapy.

• Phase: Phase 2

Details

• Lead Sponsor: Norwegian University of Science and Technology
• Collaborators: Aalborg University Hospital; Alesund Hospital; Amphia Hospital; Cantonal Hospital of St. Gallen; Ente Ospedaliero Cantonale, Bellinzona; Erasmus Medical Center; Freiburger Spital; Gävle Hospital; Haukeland University Hospital; Helse Fonna; Helse Nord-Trøndelag HF; Helse Stavanger HF; Isala; Kantonsspital Graubünden; Kantonsspital Olten; Kantonsspital Winterthur KSW; Karolinska University Hospital; Klinik Hirslanden, Zurich; Kristiansund Hospital; Levanger Hospital; Medisch Spectrum Twente; Molde Hospital; National Cancer Institute, Lithuania; Nordlandssykehuset HF; Odense University Hospital; Ôrebro University Hospital; Oslo University Hospital; Rigshospitalet, Denmark; Rijnstate Hospital; Sahlgrenska University Hospital, Sweden; Skane University Hospital; Sorlandet Hospital HF; Spital STS AG; St. Antonius Hospital; St. Olavs Hospital; The Hospital of Vestfold; The Netherlands Cancer Institute; Ullevaal University Hospital; University Hospital Inselspital, Berne; University Hospital of North Norway; University Hospital, Akershus; University Hospital, Basel, Switzerland; University Hospital, Linkoeping; Vestre Viken Hospital Trust; Volda Hospital; Zuyderland Medisch Centrum
• Treatments: Antibodies, Monoclonal; Atezolizumab